IMMX
IMMX clinical trials: Immix Biopharma, Inc.
Every trial on ClinicalTrials.gov where Immix Biopharma, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 4
- Trials linked
- 2
- As lead sponsor
- 2
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
IMMX on the catalyst calendar · IMMX registry changes
- Primary completion Oct 31, 2023Sponsor estimatePhase 1/Phase 2NCT03382340IMX-110 in Patients With Advanced Solid TumorsImmix Biopharma Australia Pty Ltd · Solid Tumor, AdultUnknown statusIMMXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 24, 2024Sponsor estimatePhase 1/Phase 2NCT05840835Study of IMX-110 in Combination With Tislelizumab in Patients With Advanced Solid TumorsImmix Biopharma, Inc. · Advanced Solid TumorUnknown statusIMMXLeadNVSCollaboratorONCCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2028Sponsor estimatePhase 3NCT07709715A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of NXC-201 Compared With Daratumumab With Cyclophosphamide, Bortezomib...Nexcella Inc. · Light Chain (AL) AmyloidosisNot yet recruitingIMMXCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 1/Phase 2NCT06097832Study of NXC-201 CAR-T in Patients With Light Chain (AL) AmyloidosisNexcella Inc. · Light Chain (AL) AmyloidosisActive, not recruitingIMMXCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 4 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner